Pregnant Women's eczema drug safety under watch
NCT ID NCT05721937
Summary
This study aims to understand if the eczema medication abrocitinib (CIBINQO) is safe for use during pregnancy. Researchers will follow 400 pregnant women with moderate-to-severe eczema—some taking the drug and some not—and track their babies' health through the first year of life. The goal is to collect information on birth outcomes and infant development without changing anyone's normal medical care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGNew York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.